دورية أكاديمية
Prevalence of plasmid-mediated AmpC β-lactamases in Escherichia coli and Klebsiella pneumonia at tertiary care hospital of Islamabad, Pakistan.
| العنوان: | Prevalence of plasmid-mediated AmpC β-lactamases in Escherichia coli and Klebsiella pneumonia at tertiary care hospital of Islamabad, Pakistan. |
|---|---|
| المؤلفون: | Shafiq M, Rahman H, Qasim M, Ayub N, Hussain S, Khan J, Naeem M |
| المصدر: | European journal of microbiology & immunology [Eur J Microbiol Immunol (Bp)] 2013 Dec; Vol. 3 (4), pp. 267-71. Date of Electronic Publication: 2013 Nov 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Akadémiai Kiado Country of Publication: Hungary NLM ID: 101569896 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2062-509X (Print) Linking ISSN: 2062509X NLM ISO Abbreviation: Eur J Microbiol Immunol (Bp) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Budapest : Akadémiai Kiadó |
| مستخلص: | Enterobacteriaceae produces AmpC β-lactamases that make them resistant to commonly used antibiotics. AmpC β-lactamases can be chromosomal-mediated or plasmid-mediated AmpC β-lactamases (PABLs). The present study was undertaken to determine the occurrence of PABLs production in clinical isolates in Escherichia coli and Klebsiella pneumoniae. Among 1328 culture positive samples, 511 isolates were identified as E. coli (81.02%, n = 414) and K. pneumonia (18.98%, n = 97). Cefoxitin resistance was observed in E. coli (19.57%, n = 81) and K. pneumoniae (22.68%, n = 22). Out of these cefoxitin resistant isolates, 40.74% (n = 33) E. coli and 54.55% (n = 12) K. pneumoniae came out to be PABL producers. Prevalence of both PABLs and ESBLs in E. coli and K. pneumoniae was 29.24% (n = 8) and 47% (n = 5), respectively. Isolates coproducing PABLs and ESBL exhibited increased minimum inhibitory concentrations (MICs) for selected cephalosporins. This study documented a high frequency of PABLs producing isolates from hospital which may lead to serious therapeutic problem. |
| References: | Global Health. 2006 Apr 07;2:6. (PMID: 16603071) Int J Environ Res Public Health. 2010 Aug;7(8):3141-9. (PMID: 20948953) Braz J Infect Dis. 2006 Feb;10(1):22-5. (PMID: 16767311) J Clin Microbiol. 2006 Feb;44(2):518-24. (PMID: 16455907) N Engl J Med. 2005 Jan 27;352(4):380-91. (PMID: 15673804) Indian J Med Microbiol. 2005 Apr;23(2):120-4. (PMID: 15928443) Expert Rev Anti Infect Ther. 2008 Oct;6(5):657-69. (PMID: 18847404) Antimicrob Agents Chemother. 1990 Apr;34(4):622-7. (PMID: 2344169) Antimicrob Agents Chemother. 2010 Mar;54(3):969-76. (PMID: 19995920) Antibiot Annu. 1956-1957;:892-7. (PMID: 13425478) J Infect. 2008 Dec;57(6):441-8. (PMID: 18990451) J Clin Microbiol. 2005 Sep;43(9):4891-4. (PMID: 16145169) Antimicrob Agents Chemother. 2002 Jan;46(1):1-11. (PMID: 11751104) J Clin Microbiol. 2005 Jul;43(7):3110-3. (PMID: 16000421) Antimicrob Agents Chemother. 2008 Sep;52(9):3244-52. (PMID: 18591273) Diagn Microbiol Infect Dis. 2006 Sep;56(1):63-8. (PMID: 16650951) Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):915-21. (PMID: 18449580) Rev Infect Dis. 1988 Jul-Aug;10(4):867-78. (PMID: 3263690) Acta Trop. 2011 Oct-Nov;120(1-2):140-5. (PMID: 21820398) |
| فهرسة مساهمة: | Keywords: E. coli; ESBLs; K. pneumoniae; PABLs; antibiogram |
| تواريخ الأحداث: | Date Created: 20131203 Date Completed: 20131202 Latest Revision: 20211021 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC3838542 |
| DOI: | 10.1556/EuJMI.3.2013.4.5 |
| PMID: | 24294496 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2062-509X |
|---|---|
| DOI: | 10.1556/EuJMI.3.2013.4.5 |